Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Jun 8
- 1 min read
06/06/2026
Cullinan Therapeutics presented initial clinical data for CLN-978 at the EULAR-2026 congress (Ref)
Cullinan Therapeutics announced that it would present initial clinical data from two ongoing Phase 1 studies of CLN-978 (CD19xCD3 T cell engager) at the EULAR-2026 congress.
Clinical activity and biomarker findings in OUTRACE SLE
Among 14 patients with ≥4 weeks follow up, a ≥4-point reduction in hSLEDAI was observed in 10 patients (71%), with 5 achieving a DORIS remission.
All lab markers of disease activity (anti-dsDNA, UPCR, C3 and C4) improved in patients with clinically significant abnormalities at baseline.
Following a single target dose of CLN-978, peripheral B cell counts were reduced by >80% from baseline in 82%, with dose-dependent recovery.
Peripheral B cell depletion below the limit of quantification (BLOQ) was achieved in 50% of those treated at target doses ≥20 µg.
Clinical activity and biomarker findings in OUTRACE RA
In this heavily pretreated population, 6 of 7 patients (86%) had high baseline disease activity. Disease activity improved in 5 of 7 patients (71%), including a DAS28-ESR remission in 1 patient treated with a single 30 μg target dose.
CLN-978 reduced RA autoantibody levels without impact on protective vaccine titers.
Peripheral blood B cell depletion BLOQ was achieved in 4 of 6 patients (67%) treated at target doses ≥20 µg.
Dose dependent B cell depletion was also observed in lymph node and synovial tissue.
CLN-978 was well tolerated across the 10 μg, 20 μg and 30 μg target dose cohorts, including in patients who received 3 administrations of the 20 μg target dose in a multi-dose regimen.
